Suchergebnisse
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know
AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.89%. Elsewhere, the Dow
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2026, AbbVie (ABBV) reported revenue of $16.99 billion, up 10.2% over the same period last year. EPS came in at $3.65, compared to $2.97 in the year-ago quarter.
The
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
AbbVie ABBV is scheduled to report second-quarter 2026 results on July 31, before the opening bell. While investor focus will primarily remain on the continued strength of the company’s blockbuster
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?
AbbVie’s ABBV oncology franchise has evolved considerably in recent years. What was once largely a hematology-focused business has expanded into solid tumors through a series of acquisitions
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie ABBV is set to report second-quarter 2026 earnings on July 31, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s sales is pinned at $16.81 billion, while
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company’s guidance of $3.57-$3.61 per share
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts
Abbott Laboratories Q2 Earnings Call Highlights
Key Points
- Interested in Abbott Laboratories? Here are five stocks we like better.
- Abbott beat expectations in Q2, reporting 4.8% comparable sales growth and adjusted EPS of $1.31. Management
Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
Key Points
- Interested in Abbott Laboratories? Here are five stocks we like better.
- Abbott Laboratories posted solid Q2 results, with 13% reported growth and 4.8% organic growth, showing Exact
Abbott Laboratories Aktie: 21-Milliarden-Deal trägt Früchte
Abbott Laboratories hat mit den Ergebnissen für das zweite Quartal 2026 die Erwartungen des…
Der Beitrag Abbott Laboratories Aktie: 21-Milliarden-Deal trägt Früchte erschien zuerst auf kapitalmarkte
ABB Aktie: Auftragseingang springt um 30 Prozent
ABB hat am 16. Juli 2026 Quartalszahlen vorgelegt, die in mehrfacher Hinsicht Rekordniveau markieren.…
Der Beitrag ABB Aktie: Auftragseingang springt um 30 Prozent erschien zuerst auf kapitalmarktex
ABB erweitert Automatisierungsangebot mit Übernahme von Rotork
AbbVie Aktie: RINVOQ punktet doppelt
Zwei EU-Zulassungen an einem Tag — das gab es für AbbVie selten. Die Europäische…
Der Beitrag AbbVie Aktie: RINVOQ punktet doppelt erschien zuerst auf kapitalmarktexperten.de.
Quelle kapitalmarktexp
AbbVie Q2 Earnings Call Highlights
Key Points
- Interested in AbbVie Inc.? Here are five stocks we like better.
- AbbVie exceeded Q2 expectations, reporting nearly $17 billion in revenue, up 10.2% year over year, and adjusted EPS of
Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Abbott (ABT) will report quarterly earnings of $1.28 per share in its upcoming release, pointing to a year-over-year increase of 1.6%. It is anticipated that
Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?
Abbott Laboratories ABT is slated to report its second-quarter 2026 results on July 16, before the opening bell.
The Zacks Consensus Estimate for the company’s second-quarter earnings per share
3 Top-Ranked Lord Abbett Mutual Funds for Long-Term Investing
Founded in 1929, Lord Abbett managed assets worth more than $ 250 billion as of March 31, 2026. This privately held company has around 184 investment professionals with an average of 18 years of
Reasons to Retain Abbott Stock in Your Portfolio for Now
Strong momentum in Abbott Laboratories' ABT Nutrition business is expected to support growth in the coming quarters. The company is driving solid growth in emerging markets within the Established